Health Canada approves new topical treatment for acne

Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc., announced Health Canada’s approval of PrCABTREO™, a topical gel for the treatment of acne vulgaris in patients 12 years of age and older. CABTREO combines three active ingredients: clindamycin phosphate, adapalene and benzoyl peroxide. Clinical studies have demonstrated its efficacy, with a treatment success rate of approximately 50% and a reduction in acne lesions of more than 70%.

The most common side effects include mild to moderate skin irritation. CABTREO will be available in Canadian pharmacies in the fourth quarter. The approval of this treatment underscores Bausch Health's commitment to providing innovative dermatology solutions in Canada.